Published in Clin J Am Soc Nephrol on May 03, 2012
Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol (2013) 1.78
Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int (2013) 1.42
Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study. J Am Heart Assoc (2014) 1.07
Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int (2016) 1.00
Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int (2016) 0.95
Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. PLoS One (2013) 0.93
Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23. J Biol Chem (2015) 0.91
Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. Nephrol Dial Transplant (2013) 0.89
FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrol Dial Transplant (2014) 0.88
The use of fibroblast growth factor 23 testing in patients with kidney disease. Clin J Am Soc Nephrol (2014) 0.86
Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One (2015) 0.85
1,25-dihydroxyvitamin D(3) regulation of fibroblast growth factor-23 expression in bone cells: evidence for primary and secondary mechanisms modulated by leptin and interleukin-6. Calcif Tissue Int (2012) 0.84
Association between parathyroid hormone levels and inflammatory markers among US adults. Mediators Inflamm (2014) 0.84
Single FGF-23 measurement and time-averaged plasma phosphate levels in hemodialysis patients. Clin J Am Soc Nephrol (2013) 0.83
Key role of the kidney in the regulation of fibroblast growth factor 23. Kidney Int (2015) 0.81
Risk of ESRD and all cause mortality in type 2 diabetes according to circulating levels of FGF-23 and TNFR1. PLoS One (2013) 0.81
Gastrointestinal phosphate handling in CKD and its association with cardiovascular disease. Am J Kidney Dis (2013) 0.81
The role of fibroblast growth factor-23 in cardiorenal syndrome. Nephron Clin Pract (2013) 0.81
Counter-regulatory paracrine actions of FGF-23 and 1,25(OH)2 D in macrophages. FEBS Lett (2016) 0.81
A longitudinal study of inflammation, CKD-mineral bone disorder, and carotid atherosclerosis after renal transplantation. Clin J Am Soc Nephrol (2014) 0.81
The Association between Fibroblast Growth Factor-23 and Vascular Calcification Is Mitigated by Inflammation Markers. Nephron Extra (2013) 0.80
Experimental Myocardial Infarction Upregulates Circulating Fibroblast Growth Factor-23. J Bone Miner Res (2015) 0.80
Deregulated Renal Calcium and Phosphate Transport during Experimental Kidney Failure. PLoS One (2015) 0.80
FGF23 and mineral metabolism in the early post-renal transplantation period. Pediatr Nephrol (2013) 0.79
Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure. PLoS One (2015) 0.79
Circulating fibroblast growth factor-23 and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities study. J Am Heart Assoc (2014) 0.78
Extrarenal effects of FGF23. Pediatr Nephrol (2016) 0.78
Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area: The Northern Manhattan Study. Arterioscler Thromb Vasc Biol (2015) 0.78
The role of bone in CKD-mediated mineral and vascular disease. Pediatr Nephrol (2014) 0.78
Effects of acute kidney injury and chronic hypoxemia on fibroblast growth factor 23 levels in pediatric cardiac surgery patients. Pediatr Nephrol (2015) 0.77
5(th) Asian PAD Workshop. Ann Vasc Dis (2014) 0.77
Urine fibroblast growth factor 23 levels in hypertensive children and adolescents. Croat Med J (2015) 0.76
Plasma Fibroblast Growth Factor 23: Clinical Correlates and Association With Cardiovascular Disease and Mortality in the Framingham Heart Study. J Am Heart Assoc (2016) 0.75
Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int (2016) 0.75
Vitamin D: a possible modifying factor linking obesity to vascular calcification in hemodialysis patients. Nutr Metab (Lond) (2017) 0.75
Inflammation regulates fibroblast growth factor 23 production. Curr Opin Nephrol Hypertens (2016) 0.75
Ironing out the cross talk between FGF23 and inflammation. Am J Physiol Renal Physiol (2016) 0.75
The Authors Reply. Kidney Int (2015) 0.75
The systemic nature of CKD. Nat Rev Nephrol (2017) 0.75
Multiple faces of fibroblast growth factor-23. Curr Opin Nephrol Hypertens (2016) 0.75
Serum fibroblast growth factor-23 and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. J Hypertens (2016) 0.75
Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review. J Adv Res (2017) 0.75
Dietary phosphate exacerbates intestinal inflammation in experimental colitis. J Clin Biochem Nutr (2017) 0.75
Subclinical Cerebrovascular Disease Increases the Risk of Incident Stroke and Mortality: The Northern Manhattan Study. J Am Heart Assoc (2017) 0.75
Fibroblast Growth Factor-23 and Frailty in Elderly Community-Dwelling Individuals: The Cardiovascular Health Study. J Am Geriatr Soc (2016) 0.75
Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder. Curr Osteoporos Rep (2017) 0.75
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med (1996) 16.98
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res (2003) 6.81
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem (2007) 4.42
Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int (1999) 4.25
Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation (2003) 3.76
The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol (2004) 3.29
Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int (2010) 3.04
Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension (2008) 2.99
Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett (1989) 2.79
FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int (2011) 2.71
Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun (2001) 2.63
Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int (2005) 2.43
Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A (2011) 2.24
Endocrine functions of bone in mineral metabolism regulation. J Clin Invest (2008) 2.19
Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int (2009) 1.93
CKD in Hispanics: Baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies. Am J Kidney Dis (2011) 1.88
Molecular control of iron transport. J Am Soc Nephrol (2007) 1.85
FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease. Kidney Int (2010) 1.81
Classification of obesity and assessment of obesity-related health risks. Obes Res (2002) 1.60
Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant (2008) 1.59
Klotho suppresses TNF-alpha-induced expression of adhesion molecules in the endothelium and attenuates NF-kappaB activation. Endocrine (2009) 1.37
Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res (2010) 1.34
Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol (2010) 1.34
Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology (2009) 1.33
Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab (2010) 1.31
Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr (2004) 1.30
Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol (2010) 1.20
Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl (2002) 1.16
Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. J Ren Nutr (2010) 1.09
Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int (2009) 1.08
Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int (1998) 1.05
TNFalpha and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics. Bone (2005) 1.04
Inflammation and vascular calcification. Blood Purif (2005) 1.00
A high calcium-phosphate product is associated with high C-reactive protein concentrations in hemodialysis patients. Nephron Clin Pract (2005) 0.99
Klotho in chronic kidney disease--what's new? Nephrol Dial Transplant (2009) 0.96
Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study. Clin J Am Soc Nephrol (2009) 0.94
Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients. Ther Apher Dial (2010) 0.90
Leptin in renal failure. J Ren Nutr (1999) 0.79
Linking long-term dietary patterns with gut microbial enterotypes. Science (2011) 17.30
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med (2014) 10.66
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Cell biology of the glomerular podocyte. Physiol Rev (2003) 6.85
Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 6.41
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol (2005) 5.76
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med (2004) 5.45
Effects of low-carbohydrate and low-fat diets: a randomized trial. Ann Intern Med (2014) 5.31
Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2007) 5.26
APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med (2013) 5.00
Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiol (2010) 4.97
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest (2007) 4.80
Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74
Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest (2004) 4.65
Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44
Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med (2009) 4.19
Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol (2009) 4.16
Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA (2011) 4.09
Modification of kidney barrier function by the urokinase receptor. Nat Med (2007) 4.01
Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol (2011) 3.83
Mouse models of diabetic nephropathy. J Am Soc Nephrol (2009) 3.74
Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 3.62
A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int (2009) 3.41
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ (2008) 3.35
Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology (2013) 3.28
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Genetic variants and associations of 25-hydroxyvitamin D concentrations with major clinical outcomes. JAMA (2012) 3.10
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol (2008) 3.00
Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med (2010) 2.97
The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med (2004) 2.94
Effects of phosphate binders in moderate CKD. J Am Soc Nephrol (2012) 2.92
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest (2011) 2.90
Validation of endogenous controls for gene expression analysis in microdissected human renal biopsies. Kidney Int (2003) 2.90
Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes (2006) 2.85
Risk factors for low serum 25-hydroxyvitamin D concentrations in otherwise healthy children and adolescents. Am J Clin Nutr (2007) 2.73
Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. Lancet (2009) 2.73
mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest (2011) 2.72
Cortical bone water: in vivo quantification with ultrashort echo-time MR imaging. Radiology (2008) 2.71
Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes (2009) 2.70
Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med (2006) 2.65
Premature deaths attributable to blood pressure in China: a prospective cohort study. Lancet (2009) 2.62
A group bridge approach for variable selection. Biometrika (2009) 2.61
Diuretics, calciuria and secondary hyperparathyroidism in the Chronic Renal Insufficiency Cohort. Nephrol Dial Transplant (2011) 2.60
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology (2007) 2.55
Enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats. Hypertension (2004) 2.54
International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone (2008) 2.53
Fat and lean BMI reference curves in children and adolescents and their utility in identifying excess adiposity compared with BMI and percentage body fat. Am J Clin Nutr (2013) 2.49
Urine neutrophil gelatinase-associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease. Kidney Int (2013) 2.48
Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study. Hypertension (2004) 2.46
Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2011) 2.46
Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis (2012) 2.42
Proteinuria and hyperglycemia induce endoplasmic reticulum stress. J Am Soc Nephrol (2008) 2.41
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev (2014) 2.35
Quantitative gene expression analysis in renal biopsies: a novel protocol for a high-throughput multicenter application. Kidney Int (2002) 2.34
Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol (2006) 2.32
Impact of navigators on completion of steps in the kidney transplant process: a randomized, controlled trial. Clin J Am Soc Nephrol (2012) 2.30
Regularized estimation in the accelerated failure time model with high-dimensional covariates. Biometrics (2006) 2.30
Height adjustment in assessing dual energy x-ray absorptiometry measurements of bone mass and density in children. J Clin Endocrinol Metab (2010) 2.29
Haemoglobin targets: we were wrong, time to move on. Lancet (2007) 2.26
Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant (2010) 2.23
Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease. Gastroenterology (2008) 2.21
HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev (2013) 2.21
Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol (2007) 2.20
Effect of Hurricane Katrina on the mortality of dialysis patients. Kidney Int (2009) 2.16
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab (2009) 2.12
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Who gets the best sleep? Ethnic and socioeconomic factors related to sleep complaints. Sleep Med (2010) 2.10
Associations between kidney function and subclinical cardiac abnormalities in CKD. J Am Soc Nephrol (2012) 2.10
Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis (2013) 2.09
Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes (2008) 2.07
Measured GFR does not outperform estimated GFR in predicting CKD-related complications. J Am Soc Nephrol (2011) 2.06